A- A A+

NIDA. People With SUDs Have Increased Risk for COVID-19 and Worse Outcomes

This Study reported;

People with a

+ substance use disorder (SUD) at any time in their lives are 1.5 times more likely to contract COVID-19 than those without an SUD, and those with a recent SUD are more than 8 times more likely. 

+ People with opioid use disorder (OUD) and African Americans are at particularly high risk for COVID-19. 

+ COVID-19 patients with SUDs are more likely to require hospitalization and to die from COVID-19 than those without SUD, with patients with OUD and African American patients at greatest risk.

(NIDA Notes, USA, 13.01.2021)


Covid Reference - 6th International Edition

Bernd-Sebastian Kamps und Christoph Hoffmann

Steinhäuser Verlag, 2021

13 January 2021. Finally, after 10 weeks, we have published the next edition of COVID Reference – The COVID Textbook (453 pages; we apologize for the delay). We dedicate this edition to Anthony Fauci who never tired of defending science.


For better or for worse? A pre–post exploration of the impact of the COVID‐19 lockdown on cannabis users. 

Cousijn, J., Kuhns, L., Larsen, H., and Kroon, E. (2021) 

Addiction, doi.org/10.1111/add.15387. 


Science Denial and COVID Conspiracy Theories: Potential Neurological Mechanisms 

and Possible Responses. 


JAMA. 2020;324:2255-2256. 


Cannabis and COVID-19: Reasons for Concern. 

van Laar MW, Oomen PE, van Miltenburg CJA, Vercoulen E, Freeman TP, Hall WD. 

Front Psychiatry. 2020 Dec 21;11:601653. doi: 10.3389/fpsyt.2020.601653. PMID: 33408655; PMCID: PMC7779403.


Experten-Web-Konferenz. Suchtbehandlung in Covid-Zeiten: der disruptive Zwang zur Innovation

JATROS Neurologie & Psychiatrie 6/20, p. 27-29

19_J_Neuro_Kon_ÖGABS Experten-Web-Konferenz_Barth final

Impact of the COVID-19 Pandemic on Patients With Alcohol Use Disorder and Associated Risk Factors for Relapse. 

Yazdi K, Fuchs-Leitner I, Rosenleitner J, Gerstgrasser NW. 

Front Psychiatry. 2020 Dec 16;11:620612. doi: 10.3389/fpsyt.2020.620612. PMID: 33391060; PMCID: PMC7772314.


HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform

Bhaskaran, Krishnan et al.

The Lancet HIV, Volume 8, Issue 1, e24 - e32 


Prioritizing incarcerated populations for COVID-19 vaccination and vaccine trials

Kronfli, Nadine et al.

EClinicalMedicine, Volume 31, 100659 


How Covid-19 has fueled unprecedented advances in medicine

The Covid-19 pandemic has reshaped the world of health and medicine. New vaccines are being developed at a pace once unimaginable. Telemedicine has replaced the doctor’s office for many. And artificial intelligence is predicting the patients at highest risk of growing severely ill. (stat ebook, USA, 06.01.2021)


Does opioid substitution treatment have a protective effect on the clinical manifestations of COVID-19? Comment on Br J Anaesth 2020; 125: e382-3. 

Eagleton M, Stokes S, Fenton F, Keenan E. 

Br J Anaesth. 2020 Nov 28:S0007-0912(20)30949-1. doi: 10.1016/j.bja.2020.11.027. Epub ahead of print. PMID: 33358041; PMCID: PMC7699021.


Down the drain: Reconsidering routine urine drug testing during the COVID-19 pandemic. 

Pytell JD, Rastegar DA. 

J Subst Abuse Treat. 2021 Jan;120:108155. doi: 10.1016/j.jsat.2020.108155. Epub 2020 Oct 5. PMID: 33298297; PMCID: PMC7534596.


Review of opioid risk assessment tools with the growing need for telemedicine. 

Ogilvie CB, Jotwani R, Joshi J, Gulati A, Mehta N. 

Pain Manag. 2020 Dec 22. doi: 10.2217/pmt-2020-0064. Epub ahead of print. PMID: 33350355.


Can Kratom (Mitragyna speciosa) Alleviate COVID-19 Pain? A Case Study. 

Metastasio A, Prevete E, Singh D, Grundmann O, Prozialeck WC, Veltri C, Bersani G, Corazza O. 

Front Psychiatry. 2020 Nov 19;11:594816. doi: 10.3389/fpsyt.2020.594816. PMID: 33329145; PMCID: PMC7717955.


Current and Future Potential Impact of COVID-19 on Kratom (Mitragyna speciosa Korth.) Supply and Use. 

Singh D, Brown PN, Cinosi E, Corazza O, Henningfield JE, Garcia-Romeu A, McCurdy CR, McMahon LR, Prozialeck WC, Smith KE, Swogger MT, Veltri C, Walsh Z, Grundmann O. 

Front Psychiatry. 2020 Nov 26;11:574483. doi: 10.3389/fpsyt.2020.574483. PMID: 33324252; PMCID: PMC7726130.


The Healthy Brain and Child Development Study-Shedding Light on Opioid Exposure, COVID-19, and Health Disparities. 

Volkow ND, Gordon JA, Freund MP. 

JAMA Psychiatry. 2020 Dec 9. doi: 10.1001/jamapsychiatry.2020.3803. Epub ahead of print. PMID: 33295951.


Global Perspective and Ways to Combat Stigma Associated with COVID-19. 

Adiukwu F, Bytyçi DG, Hayek SE, Gonzalez-Diaz JM, Larnaout A, Grandinetti P, Nofal M, Pereira-Sanchez V, Ransing R, Shalbafan M, Soler-Vidal J, Syarif Z, Teixeira ALS, da Costa MP, Ramalho R, Orsolini L. 

Indian J Psychol Med. 2020 Nov 9;42(6):569-574. doi: 10.1177/0253717620964932. PMID: 33354085; PMCID: PMC7735248.


Monitoring drug consumption in Innsbruck during coronavirus disease 2019 (COVID-19) lockdown by wastewater analysis. 

Kreidl M, Huber S, Grander J, Haslacher S, Singer K, Schlapp-Hackl M, Sorg M, Erber H, Oberacher H. 

Sci Total Environ. 2020 Nov 23;757:144006. doi: 10.1016/j.scitotenv.2020.144006. Epub ahead of print. PMID: 33310574; PMCID: PMC7681035.


Trajectories of anxiety and depressive symptoms during enforced isolation due to COVID-19 in England: a longitudinal observational study

Fancourt, Daisy et al.

The Lancet Psychiatry, Volume 0, Issue 0 


Rethinking Covid-19 Test Sensitivity - A Strategy for Containment. 

Mina MJ, Parker R, Larremore DB. 

N Engl J Med. 2020 Nov 26;383(22):e120. doi: 10.1056/NEJMp2025631. Epub 2020 Sep 30. PMID: 32997903.


Impacts of COVID-19 on residential treatment programs for substance use disorder. 

Pagano A, Hosakote S, Kapiteni K, Straus ER, Wong J, Guydish JR. 

J Subst Abuse Treat. 2020 Dec 17:108255. doi: 10.1016/j.jsat.2020.108255. Epub ahead of print. PMID: 33375986.


Association of substance use disorders and drug overdose with adverse COVID-19 outcomes in New York City: January-October 2020. 

Allen B, El Shahawy O, Rogers ES, Hochman S, Khan MR, Krawczyk N. 

J Public Health (Oxf). 2020 Dec 26:fdaa241. doi: 10.1093/pubmed/fdaa241. Epub ahead of print. PMID: 33367823.


Impact of COVID-19 Pandemic on Drug Overdoses in Indianapolis. 

Glober N, Mohler G, Huynh P, Arkins T, O'Donnell D, Carter J, Ray B. 

J Urban Health. 2020 Dec;97(6):802-807. doi: 10.1007/s11524-020-00484-0. Epub 2020 Oct 1. PMID: 33005988; PMCID: PMC7529089.


COVID-19 survey among people who use drugs in three cities in Norway. 

Welle-Strand GK, Skurtveit S, Clausen T, Sundal C, Gjersing L. 

Drug Alcohol Depend. 2020 Dec 1;217:108302. doi: 10.1016/j.drugalcdep.2020.108302. Epub 2020 Sep 18. PMID: 32961453; PMCID: PMC7500397.


A double-edged sword of using opioids and COVID-19: a toxicological view. 

Ataei M, Shirazi FM, Lamarine RJ, Nakhaee S, Mehrpour O. A 

Subst Abuse Treat Prev Policy. 2020 Dec 3;15(1):91. doi: 10.1186/s13011-020-00333-y. PMID: 33272308; PMCID: PMC7711252.


Multiple potential targets of opioids in the treatment of acute respiratory distress syndrome from COVID-19. 

Cismaru CA, Cismaru GL, Nabavi SF, Ghanei M, Burz CC, Nabavi SM, Berindan Neagoe I. 

J Cell Mol Med. 2020 Nov 19:10.1111/jcmm.15927. doi: 10.1111/jcmm.15927. Epub ahead of print. PMID: 33211389; PMCID: PMC7753383.


Clinical Trials for Substance Use Disorders in the Age of Covid-19. 

Brezing CA, Luo SX, Mariani JJ, Levin FR. Digital 

J Addict Med. 2020 Dec;14(6):e297-e302. doi: 10.1097/ADM.0000000000000733. PMID: 32956164; PMCID: PMC7647443.


'The dual pandemic' of suicide and COVID-19: A biopsychosocial narrative of risks and prevention. 

Banerjee D, Kosagisharaf JR, Sathyanarayana Rao TS.

Psychiatry Res. 2020 Nov 18:113577. doi: 10.1016/j.psychres.2020.113577. Epub ahead of print. PMID: 33229123; PMCID: PMC7672361.


Telepsychiatry and Addiction Treatment. 

Mohan A, Ambekar A. 

Indian J Psychol Med. 2020 Oct 6;42(5 Suppl):52S-56S. doi: 10.1177/0253717620958169. PMID: 33354065; PMCID: PMC7736732.


Drug use during a pandemic: Convergent risk of novel coronavirus and invasive bacterial and viral infections among people who use drugs. 

Jacka BP, Phipps E, Marshall BDL. 

Int J Drug Policy. 2020 Sep;83:102895. doi: 10.1016/j.drugpo.2020.102895. Epub 2020 Jul 29. PMID: 32741718; PMCID: PMC7388892.